I-Mab
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a IMAB research report →
Range $7 – $9
Price Chart
About the company
I-Mab is a biopharmaceutical company, operating at the clinical stage, dedicated to the discovery, advancement, and commercialization of biologic therapies. Its core mission is to address critical medical needs in both oncology and autoimmune diseases. The company boasts a comprehensive pipeline of drug candidates.
- CEO
- Xi-Yong Fu
- IPO
- 2020
- Employees
- 32
- HQ
- Rockville, US
Get TickerSpark's AI analysis on IMAB
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $542.01M
- P/E
- -21.72
- PEG
- -0.26
- P/S
- 0.00
- P/B
- 19.41
- EV/EBITDA
- -45.73
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -0.59%
- ROIC
- -94.82%
Latest fiscal year · YoY change
- Revenue
- $0-100.0%
- Gross Profit
- $-978,490-121.8%
- Op Income
- $-51,409,031
- Net Income
- $-22,222,718+98.5%
- EPS
- $-0.62+96.5%
- OCF Growth
- +27.5%
- FCF Growth
- +27.6%
- 52W High
- $6.79
- 52W Low
- $0.59
- 50D MA
- $4.44
- 200D MA
- $2.39
- Beta
- 1.46
- RSI (14)
- 46
- Avg Volume
- 1.85M
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Get the IMAB Q2 '26 earnings-call summary
Create a free account to generate an AI summary of this call — key takeaways, results & guidance, CEO/CFO commentary, Q&A, and a bull vs bear read. Ready in about a minute, and it'll be live for everyone.
Create free account →Already have an account? Log in
- Free Float
- 99.7%
- Shares Outstanding
- 81.83M
- Float Shares
- 81.60M
of shares held by institutions
45 13F filers
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Point72 Hong Kong Ltd | 561.37K | ▲ 561.37K |
| Edbi Pte Ltd | 222.14K | 0 |
Held by 15 ETFs
Biggest fund positions in IMAB by dollar value.
Our IMAB coverage
Recent articles, reports, and earnings notes.
No research on IMAB yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate IMAB report →I-MAB (Nasdaq: IMAB) Transitions to NovaBridge Biosciences (Nasdaq: NBP) with Trading Effective October 30, 2025 New Brand and Logo to Reflect Strategic Transformation to a Global Biotech Platform
globenewswire.com · Oct 29
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of I-Mab - IMAB
prnewswire.com · Oct 28
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of I-Mab - IMAB
prnewswire.com · Oct 23
I-Mab To Present Positive Updated Givastomig Monotherapy Data at 2025 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference on October 23, 2025
globenewswire.com · Oct 22
I-Mab (IMAB) Discusses Business Transformation Strategy and Plans for Accelerated Growth Transcript
seekingalpha.com · Oct 17
I-Mab Announces Intention to Undertake Strategic Transformation to Global Biotech Platform, to Pursue Hong Kong IPO, and Rebrand as NovaBridge Biosciences
globenewswire.com · Oct 16
I-Mab to Present Short-Talk on Updated Givastomig Monotherapy Data at the 2025 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference
globenewswire.com · Oct 14
I-Mab Sponsored ADR (IMAB) Is Up 24.14% in One Week: What You Should Know
zacks.com · Oct 10
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.